CRDL

Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a clinical-stage Canadian biopharmaceutical company founded in 2017 and headquartered in Oakville, Ontario. The company went public in January 2019 and focuses on developing innovative therapies to treat cardiovascular diseases through anti-fibrotic and anti-inflammatory approaches. As a clinical-stage company, Cardiol has no commercial products yet and is currently conducting Phase II/III trials for its lead drug candidate, CardiolRx, targeting heart-related conditions including COVID-19 cardiovascular complications and acute myocarditis.